Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma M Dimou, MK Angelopoulou, GA Pangalis, G Georgiou, C Kalpadakis, ... Leukemia & lymphoma 53 (8), 1481-1487, 2012 | 35 | 2012 |
COVID‑19 induced hypoparathyroidism: A case report VE Georgakopoulou, P Avramopoulos, P Papalexis, A Bitsani, ... Experimental and Therapeutic Medicine 23 (5), 1-5, 2022 | 17 | 2022 |
Prognostic significance of serum free light chains in chronic lymphocytic leukemia K Sarris, D Maltezas, E Koulieris, V Bartzis, T Tzenou, S Sachanas, ... Advances in Hematology 2013, 2013 | 16 | 2013 |
Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib G Georgiou, A Efthymiou, I Vardounioti, G Boutsikas, MK Angelopoulou, ... Leukemia 26 (4), 824-826, 2012 | 16 | 2012 |
Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological malignancies. A single-center retrospective analysis M Dimou, T Iliakis, D Maltezas, A Bitsani, S Kalyva, A Koudouna, ... Anticancer Research 38 (7), 4187-4191, 2018 | 14 | 2018 |
Exacerbation of bronchiectasis by Pseudomonas putida complicating COVID‑19 disease: A case report VE Georgakopoulou, P Avramopoulos, P Papalexis, A Bitsani, ... Experimental and Therapeutic Medicine 22 (6), 1-4, 2021 | 10 | 2021 |
Effectiveness of oral nirmatrelvir/ritonavir vs. intravenous three-day remdesivir in preventing progression to severe COVID-19: a single-center, prospective, comparative, real … D Basoulis, A Tsakanikas, A Gkoufa, A Bitsani, G Karamanakos, ... Viruses 15 (7), 1515, 2023 | 8 | 2023 |
Factors predicting poor outcomes of patients treated with tocilizumab for COVID‑19‑associated pneumonia: A retrospective study VE Georgakopoulou, D Basoulis, PM Voutsinas, S Makrodimitri, ... Experimental and Therapeutic Medicine 24 (6), 1-12, 2022 | 7 | 2022 |
Pembrolizumab-induced remission after failure of axicabtagene ciloleucel: case report and literature review M Dimou, A Bitsani, W Bethge, P Panayiotidis, TP Vassilakopoulos in vivo 35 (6), 3401-3406, 2021 | 7 | 2021 |
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data E Gavriilaki, E Nikolousis, EE Koravou, S Dimou-Besikli, C Kartsios, ... Frontiers in Medicine 10, 1226114, 2023 | 4 | 2023 |
Asymptomatic SARS‑CoV‑2 infection in an unvaccinated 97‑year‑old woman: A case report VE Georgakopoulou, P Papalexis, C Sanos, A Bitsani, A Garmpi, ... Biomedical Reports 15 (6), 1-5, 2021 | 4 | 2021 |
The contribution of prognostic factors to the better management of multiple myeloma patients MC Kyrtsonis, D Maltezas, E Koulieris, K Bitsani, I Pessach, A Efthymiou, ... Multiple Myeloma—An Overview, 145-174, 2012 | 4 | 2012 |
Caplacizumab for acquired thrombotic thrombocytopenic purpura: real-world multicenter data on re-administration and plasma exchange free treatment E Gavriilaki, E Koravou, S Dimou-Mpesikli, E Nikolousis, A Banti, ... Blood 140 (Supplement 1), 8503-8504, 2022 | 3 | 2022 |
COVID-19-associated pneumonia in Swyer-James-MacLeod syndrome: A case report A Bitsani, A Garmpi, P Avramopoulos, DA Spandidos, G Fotakopoulos, ... Medicine International 2 (5), 1-4, 2022 | 2 | 2022 |
Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease “sanctuary … M Dimou, A Bitsani, M Roumelioti, A Dimitrakopoulou, T Iliakis, V Pardalis, ... Clinical Case Reports 9 (4), 2249-2253, 2021 | 2 | 2021 |
Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from … M Dimou, V Pardalis, T Iliakis, A Bitsani, I Grafakos, S Kalyva, ... Blood 134, 3429, 2019 | 2 | 2019 |
Assessment of frailty in a multiple myeloma (MM) series E Nikolaou, D Maltezas, T Tzenou, T Iliakis, E Koulieris, M Dimou, ... HAEMATOLOGICA 101, 539-539, 2016 | 2 | 2016 |
Antiphospholipid syndrome in cardiovascular disease and cancer I Pessach, E Kyriakou, E Kalampokas, T Kalampokas, A Bitsani, ... European Journal of Haematology 111 (6), 834-843, 2023 | 1 | 2023 |
Prognostic significance of IDH1 and IDH2 mutations in Greek patients with newly diagnosed AML A Bitsani, A Efthymiou, M Roumelioti, E Staikou, A Stefanou, ... Haema 13 (1-2), 31-42, 2022 | 1 | 2022 |
Validation of frailty assessment in multiple myeloma (MM) patients E Nikolaou, P Papaioannou, S Kotsanti, P Petsa, D Maltezas, T Tzenou, ... Clinical Lymphoma, Myeloma and Leukemia 17 (1), e137, 2017 | 1 | 2017 |